Since the dawn of COVID-19, the U.S. Government, using American taxpayer funds, has paid Pfizer over $20 billion for its antiviral drug Paxlovid. Notably, that staggering amount is in addition to the tens of billions issued to Pfizer for its failed Comirnaty jab. Like Pfizer’s deadly jab, from the outset, Paxlovid’s clinical trial data demonstrated the drug had little to no success in preventing or treating SARS-CoV-2. Two years later, clinical trial data, officially released yesterday, proves as much, leaving those of us footing the tab hoodwinked.

The obvious question is, why keep pushing such an expensive drug if it’s proven ineffective? For starters, as noted by Dr. Pierre Kory, keeping Paxlovid (nirmatrelvir) front and center was critical in the destruction of Ivermectin—the miracle drug that could destroy the multi-billion COVID-19 injection and patented pharmaceutical market, which was swiftly crafted when the pandemic hit. Commenting on the billions made off Paxlovid that would’ve been non-existent if Ivermectin was in the game, Kory remarked:

“This pandemic would have been over if everybody was on Ivermectin, and that’s why they had to destroy it.”

As has been the ruse throughout the pandemic, Paxlovid’s ineffective clinical trial results—again, funded by Pfizer and released almost two years later despite the trial being terminated in June 2022—barely made the news. But why would they? Pfizer funds the media propaganda machine that controls the scary COVID monster. Instead, Americans continue to be brainwashed by mainstream media ads promoting Paxlovid’s effectiveness. Meanwhile, Pfizer shifted its focus from exploiting Paxlovid to treat “standard risk” patients—where it was proven to make no difference—to declaring it is effective in fighting COVID-19 in “high risk” patients.

Let’s first take a look at Pfizer’s clinical trial concentrating on “standard risk” patients. Pfizer defined them as “patients who were fully vaccinated against COVID-19 and who had at least one risk factor for severe disease, as well as patients without such risk factors who had never been vaccinated against COVID-19 or had not been vaccinated within the previous year, were eligible for participation.” For context, the study’s risk factors for severe disease included advanced age (50+), male sex, obesity, immunosuppression, and diabetes. The trial, which consisted of 1296 participants, quickly concluded that “the time to sustained alleviation of all signs and symptoms of COVID-19 did not differ significantly between participants who received nirmatrelvir-ritonavir and those who received the placebo.” They should have stopped there.

Now, let’s look at Pfizer’s separate clinical trial concentrating on “high-risk” patients. Pfizer characterized them as a group in which “symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe COVID-19 were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.” The study defined “high-risk” as “persons with particular characteristics such as older age, current smoking, or underlying clinical conditions such as cardiovascular disease, diabetes, obesity, and cancer,” noting these patients are at high risk for severe COVID-19 and “associated adverse outcomes.” This list encompasses the majority of those who died while sick with COVID.

Besides the list of serious health conditions above, it has been well-established that many of the deaths labeled as “COVID” deaths were indeed due to additional factors, such as the administration of remdesivir and other drugs, being put on a ventilator, hospital neglect, mistakes, and so on. Immediately, one must recognize that Pfizer’s “high-risk” study took place during that timeframe, and thus, like so many Big Pharma-funded trials, the results are undoubtedly skewed. Indeed, the study states that “COVID–19–related hospitalization or death from any cause through day 28 … were evaluated.”

Pfizer’s lucrative determination that Paxlovid—whose FDA’s emergency use authorization (EUA) ended on March 13, 2024, and was transitioned to FDA-approved Paxlovid—is effective as a prescription treatment for mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, hangs on the fact that, out of its 2246 trial participants, all deaths—there were thirteen—were in patients in the placebo group. However, the missing piece of the puzzle is how advanced these patients’ pre-existing conditions were. Is their pre-existing condition what ultimately killed them? It is a Pfizer-funded trial, after all. Likewise, while in the hospital, were these trial patients treated like Grace Schara, whose untimely hospital death during the pandemic (which included Pfizer’s drugs) forever altered the lives of those who love her?

Despite its questionable and lackluster performance, like the ongoing COVID-19 jabs and boosters, Paxlovid is not going away. Without a doubt, despite subpar clinical trial results for several of its COVID drugs, including the COVID-19 jab, Pfizer CEO Albert Bourla’s arrangement with the federal government overrides the health of the American people. Last October, the Department of Health and Human Services (HHS) reached an agreement with Pfizer that “extends patient access to Paxlovid, maximizes taxpayer investment, and begins Paxlovid’s transition to the commercial market in November 2023.” The agreement ensures that Medicare, Medicaid, and uninsured patients can access Paxlovid for free through the end of 2024. It also guarantees that “up-to-date product will be refreshed from Pfizer through 2028” and creates a stockpile of Paxlovid for “future emergencies.”

Remember, without asking taxpayers if they wanted to invest in Paxlovid, in 2021, the Biden administration secured a $10.6 billion contract with Pfizer to supply 20 million courses of Paxlovid as an early at-home treatment during high-risk cases, thanks to Pfizer’s clinical trial results—a taxpayer bargain at a hefty $530 per treatment. A few months later, in late 2022, Biden purchased an additional 3.7 million doses of Paxlovid for nearly $2 billion. Also, in 2022, the U.S. Army contracted with Pfizer for a $4.8 billion contract modification and a $442 million contract modification to supply Paxlovid to troops in Maryland.

To be effective, Paxlovid (nirmatrelvir) is combined with the HIV drug ritonavir. It makes you wonder, should VAIDS be a concern? According to a November 2022 paper published in the Journal of the American College of Cardiology, the combination has dangerous interactions with some of the most common pharmaceutical drugs for heart disease. Specifically, it reacts negatively with the CYP450 pathway, which metabolizes numerous medications. Moreover,  patients could die if they take Paxlovid alongside other interactive drugs, including anti-seizure medications, drugs for irregular heart rhythms, medicines for high blood pressure and high cholesterol, antidepressants and anti-anxiety medications, steroids, HIV treatments, blood thinners, and erectile dysfunction medications.

When you realize that Paxlovid is effectively a rip-off of Ivermectin, making a handful of people super rich, the only option in the best interest of the American people—to “maximize taxpayer investment”—would be to take it off the market and ask for a refund. We know that won’t happen, but now that the FDA has agreed to permanently remove social media posts against Ivermectin (with many thanks to a lawsuit filed in 2022 by Drs. Paul Marik, Mary Talley Bowden, and Robert Apter), let’s hope more Americans speak up and choose Ivermectin over Paxlovid when seeking treatment for COVID-19. We cannot continue to fund Big Pharma’s quest to make us sicker while it pockets billions.

Generic avatar

Tracy Beanz & Michelle Edwards

Tracy Beanz is an investigative journalist with a focus on corruption. She is known for her unbiased, in-depth coverage of the COVID-19 pandemic. She hosts the Dark to Light podcast, found on all major video and podcasting platforms. She is a bi-weekly guest on the Joe Pags Radio Show, has been on Steve Bannon’s WarRoom and is a frequent guest on Emerald Robinson’s show. Tracy is Editor-in-chief at